Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
2.

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC.

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. No abstract available.

3.

Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.

Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA.

Nat Commun. 2019 Jan 25;10(1):449. doi: 10.1038/s41467-019-08304-z.

4.

Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity.

Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S, Robbins PF, Rosenberg SA.

Sci Immunol. 2019 Jan 11;4(31). pii: eaao4310. doi: 10.1126/sciimmunol.aao4310.

5.

Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA.

JCI Insight. 2018 Oct 4;3(19). pii: 122467. doi: 10.1172/jci.insight.122467.

6.

T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.

Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Wunderlich JR, Danforth DN, Somerville RPT, Rosenberg SA.

Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.

PMID:
29853601
7.

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA.

Clin Cancer Res. 2017 Jan 15;23(2):351-362. doi: 10.1158/1078-0432.CCR-16-0906. Epub 2016 Oct 7.

8.

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.

Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner J, Trebska-McGowan K, Crystal JS, Rosenberg SA.

Cancer Immunol Res. 2016 Sep 2;4(9):734-43. doi: 10.1158/2326-6066.CIR-16-0001. Epub 2016 Jun 28.

9.

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA.

Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.

10.

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.

Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF 2nd, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ.

PLoS One. 2015 Jun 1;10(6):e0128151. doi: 10.1371/journal.pone.0128151. eCollection 2015.

11.

Clinical applications of gamma delta T cells with multivalent immunity.

Deniger DC, Moyes JS, Cooper LJ.

Front Immunol. 2014 Dec 11;5:636. doi: 10.3389/fimmu.2014.00636. eCollection 2014. Review.

12.

Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC Jr, Champlin RE, Cooper LJ.

Clin Cancer Res. 2014 Nov 15;20(22):5708-19. doi: 10.1158/1078-0432.CCR-13-3451. Epub 2014 May 15.

13.

Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ.

Mol Ther. 2013 Mar;21(3):638-47. doi: 10.1038/mt.2012.267. Epub 2013 Jan 8.

14.

Targeting and penetration of virus receptor bearing cells by nanoparticles coated with envelope proteins of Moloney murine leukemia virus.

Deniger DC, Kolokoltsov AA, Moore AC, Albrecht TB, Davey RA.

Nano Lett. 2006 Nov;6(11):2414-21.

PMID:
17090066

Supplemental Content

Loading ...
Support Center